Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionTreatment
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment